1887

Chapter 7 : Emerging and Reemerging Infectious Diseases

Authors: Peter H. Gilligan1, M. Lynn Smiley3, Daniel S. Shapiro5
VIEW AFFILIATIONS HIDE AFFILIATIONS
Affiliations: 1: Director, Clinical Microbiology-Immunology Laboratories University of North Carolina Hospitals; 2: Professor, Microbiology-Immunology and Pathology University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514; 3: Senior Vice President of Clinical Research, Trimeris, Inc. Durham, North Carolina; 4: Clinical Professor, Medicine (Infectious Diseases) University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514; 5: Director, Clinical Microbiology and Molecular Diagnostics Laboratories Boston Medical Center; 6: Associate Professor, Medicine, Pathology and Laboratory Medicine Boston University School of Medicine, Boston, Massachusetts 02118
Content Type: Textbook
Publication Year: 2003

Category: Clinical Microbiology; Best-Selling Textbook

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Preview Magnify
Zoom in
Zoomout

Emerging and Reemerging Infectious Diseases, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555816353/9781555812072_Chap07-1.gif /docserver/preview/fulltext/10.1128/9781555816353/9781555812072_Chap07-2.gif

Abstract:

A new infectious disease problem emerged in October 2001. spores used to intentionally sicken and, in five instances, kill individuals generally failed to infect the bioterrorists’ targets, highly visible members of the media and government. Rather, they infected people who handled contaminated mail, the vehicle used to transmit this agent. The emergence of a number of bacteria resistant to multiple antimicrobial agents has caused serious concern in the medical community. Nosocomial infections due to multidrug-resistant organisms have become a problem of increasing seriousness. In the early 1990s, strains resistant to all antimicrobial agents with the exception of vancomycin became a common cause of nosocomial infection. These organisms, called methicillin-resistant (MRSA), along with another important nosocomial pathogen, , were treated with vancomycin. The resulting antimicrobial pressure is believed to have made a major contribution to the emergence of another nosocomial pathogen, vancomycin-resistant enterococci (VRE). Bacteremia due to this organism has a high mortality rate. Multidrug-resistant organisms, such as aminoglycoside-resistant , have long been recognized as important nosocomial pathogen. The recognition of a variant of Creutzfeldt-Jakob disease in the United Kingdom and France, which has been associated with the consumption of beef from herds with bovine spongiform encephalopathy (BSE), has caused a reexamination of feeding practices of domestic animals. New variants of the influenza A virus may have emerged through recombination events between avian and human viral strains.

Citation: Gilligan P, Smiley M, Shapiro D. 2003. Emerging and Reemerging Infectious Diseases, p 354-406. In Cases in Medical Microbiology and Infectious Diseases, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816353.ch7
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Emerging and Reemerging Infectious Diseases
Citation: Gilligan P, Smiley M, Shapiro D. 2003. Emerging and Reemerging Infectious Diseases, p 354-406. In Cases in Medical Microbiology and Infectious Diseases, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816353.ch7
/content/10.1128/9781555816353.chap7.fig7-1
Figure 1
10.1128/9781555816353/fig59-1_thmb.gif
10.1128/9781555816353/fig59-1.gif
Image of Figure 1
Figure 1

Citation: Gilligan P, Smiley M, Shapiro D. 2003. Emerging and Reemerging Infectious Diseases, p 354-406. In Cases in Medical Microbiology and Infectious Diseases, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816353.ch7
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555816353.chap7.fig7-2
Figure 1
10.1128/9781555816353/fig63-1_thmb.gif
10.1128/9781555816353/fig63-1.gif
Image of Figure 1
Figure 1

Citation: Gilligan P, Smiley M, Shapiro D. 2003. Emerging and Reemerging Infectious Diseases, p 354-406. In Cases in Medical Microbiology and Infectious Diseases, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816353.ch7
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555816353.chap7.fig7-3
Figure 1
10.1128/9781555816353/fig64-1_thmb.gif
10.1128/9781555816353/fig64-1.gif
Image of Figure 1
Figure 1

Citation: Gilligan P, Smiley M, Shapiro D. 2003. Emerging and Reemerging Infectious Diseases, p 354-406. In Cases in Medical Microbiology and Infectious Diseases, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816353.ch7
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555816353.chap7.fig7-4
Figure 1
10.1128/9781555816353/fig65-1_thmb.gif
10.1128/9781555816353/fig65-1.gif
Image of Figure 1
Figure 1

Citation: Gilligan P, Smiley M, Shapiro D. 2003. Emerging and Reemerging Infectious Diseases, p 354-406. In Cases in Medical Microbiology and Infectious Diseases, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816353.ch7
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555816353.chap7.fig7-5
Figure 2
10.1128/9781555816353/fig65-2_thmb.gif
10.1128/9781555816353/fig65-2.gif
Image of Figure 2
Figure 2

Citation: Gilligan P, Smiley M, Shapiro D. 2003. Emerging and Reemerging Infectious Diseases, p 354-406. In Cases in Medical Microbiology and Infectious Diseases, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816353.ch7
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555816353.chap7.fig7-6
Figure 1
10.1128/9781555816353/fig66-1_thmb.gif
10.1128/9781555816353/fig66-1.gif
Image of Figure 1
Figure 1

Citation: Gilligan P, Smiley M, Shapiro D. 2003. Emerging and Reemerging Infectious Diseases, p 354-406. In Cases in Medical Microbiology and Infectious Diseases, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816353.ch7
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555816353.chap7.fig7-7
Figure 1
10.1128/9781555816353/fig68-1_thmb.gif
10.1128/9781555816353/fig68-1.gif
Image of Figure 1
Figure 1

Citation: Gilligan P, Smiley M, Shapiro D. 2003. Emerging and Reemerging Infectious Diseases, p 354-406. In Cases in Medical Microbiology and Infectious Diseases, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816353.ch7
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555816353.chap7
1. Bernard, G. R.,, J. L. Vincent,, P. F. Laterre,, S. P. LaRosa,, J. F. Dhainaut,, A. Lopez-Rodriguez,, J. S. Steingrub,, G. E. Garber,, J. D. Helterbrand,, E. W. Ely,, and C. J. Fisher, Jr. 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344: 699– 709.
2. Bone, R. C.,, C. J. Grodzin,, and R. A. Balk. 1997. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 112: 235– 243.
3. Wheeler, A. P.,, and G. R. Bernard. 1999. Treating patients with severe sepsis. N. Engl. J. Med. 340: 207– 214.
1. Centers for Disease Control and Prevention. 1996. Progress toward elimination of neonatal tetanus—Egypt, 1988-1994. Morb. Mortal. Wkly. Rep. 45: 89– 92.
2. Centers for Disease Control and Prevention. 1998. Tetanus surveillance— United States, 1995-1997. Morb. Mortal. Wkly. Rep. 47(SS-2): 1– 13.
3. Galazka, A.,, and F. Gasse. 1995. The present status of tetanus and tetanus vaccination. Curr. Top. Microbiol. Immunol. 195: 31– 53.
4. Weinstein, L. 1973. Tetanus. N. Engl. J. Med. 289: 1293– 1296.
1. Ho, D. D.,, A. V. Neumann,, A. S. Perelson,, W. Chen,, J. M. Leonard,, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123– 126.
2. Mellors, J. W.,, A. Munoz,, J. V. Giorgi,, J. B. Margolick,, C. J. Tassoni,, P. Gupta,, L. A. Kingsley,, J. A. Todd,, A. J. Saah,, R. Detels,, J. P. Phair,, and C. R. Rinaldo, Jr. 1997. Plasma viral load and CD4 + lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126: 946– 954.
3. Saag, M. S.,, M. Holodnix,, D. R. Kuritzkes,, W. A. O’Brien,, R. Coombs,, M. E. Poscher,, D. M. Jacobsen,, G. M. Shaw,, D. D. Richman,, and P. A. Volberding. 1996. HIV viral load markers in clinical practice. Nat. Med. 2: 625– 629.
4. Schacker, T.,, A. C. Collier,, J. Hughes,, T. Shea,, and L. Corey. 1996. Clinical and epidemiologic features of primary HIV infection. Ann. Intern. Med. 125: 257– 264.
5. U.S.Department of Health and Human Services. 2001. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents (http://hisatis.org/ trtgdlns.html).
1. Centers for Disease Control and Prevention. 1998. Recommendations for the prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morb. Mortal. Wkly. Rep. 47(RR-19): 1– 39.
2. Jaeckel, E.,, M. Cornberg,, H. Wedemeyer,, T. Santantonio,, J. Mayer,, M. Zankel,, G. Pastore,, M. Dietrich,, C. Trautwein,, and M. Manns for the German Acute Hepatitis C Therapy Group. 2001. Treatment of acute hepatitis C with interferon alfa-2b. N. Engl. J. Med. 345: 1452– 1457.
3. Lauer, G. M.,, and B. D. Walker. 2001. Hepatitis C virus infection. N. Engl. J. Med. 345: 41– 52.
4. Zein, N. N. 2000. Clinical significance of hepatitis C virus genotypes. Clin. Microbiol. Rev. 13: 223– 235.
1. Gilligan, P. H. 1999. Escherichia coli: EAEC, EHEC, EIEC, ETEC. Clin. Lab. Med. 19: 505– 521.
2. Kiyokawa, N.,, T. Taguchi,, T. Mori,, H. Uchida,, N. Sato,, T. Takeda,, and J. Fujimoro. 1998. Induction of apoptosis in normal renal tubular epithelial cells by Escherichia coli Shiga toxins 1 and 2. J. Infect. Dis. 178: 178– 184.
3. Nataro, J. P.,, and J. B. Kaper. 1998. Diarrheagenic Escherichia coli. Clin. Microbiol. Rev. 11: 142– 201.
4. Safdar, S.,, A. Said,, R. E. Gangnon,, and D. G. Maki. 2002. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA 288: 996– 1001.
5. Wong, C. S.,, S. Jelacic,, R. L. Habeeb,, S. L. Watkins,, and P. I. Tarr. 2000. The risk of hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N. Engl. J. Med. 342: 1930– 1936.
1. Centers for Disease Control and Prevention. 2000. Imported dengue—United States, 1997 and 1998. Morb. Mortal. Wkly. Rep. 49: 248– 253.
2. Gill, J.,, L. M. Stark,, and G. G. Clark. 2000. Dengue surveillance in Florida, 1997-98. Emerg. Infect. Dis. 6: 30– 35.
3. Rigau-Perez, J. G.,, G. G. Clark,, D. J. Gubler,, P. Reiter,, E. J. Sanders,, and A. V. Vorndam. 1998. Dengue and dengue haemorrhagic fever. Lancet 352: 971– 977.
1. Brown, L. M. 2000. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol. Rev. 22: 283– 297.
2. Lassen, A. T.,, F. M. Pedersen,, P. Bytzer,, and O. B. Schaffalitzky de Muckadell. 2000. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial. Lancet 356: 455– 460.
3. Uemura, N.,, S. Okamoto,, S. Yamamoto,, N. Matsumura,, S. Yamaguchi,, M. Yamakido,, K. Taniyama,, N. Sasaki,, and R. J. Schlemper. 2001. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 345: 784– 789.
4. Vaira, D.,, P. Malfertheiner,, F. Megraud,, A. T. Axon,, M. Deltenre,, A. M. Hirschl,, G. Gasbarrini,, C. O’Morain,, J. M. Garcia,, M. Quina,, G. N. Tytgat, and the HpSA European Study Group. 1999. Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. Lancet 354: 30– 33.
1. Bakken, J. S.,, and J. S. Dumler. 2000. Human granulocytic ehrlichiosis. Clin. Infect. Dis. 31: 554– 560.
2. Belongia, E. A.,, K. D. Reed,, P. D. Mitchell,, P.-H. Chyou,, N. Mueller-Rizner,, M. F. Finkel,, and M. E. Schriefer. 1999. Clinical and epidemiological features of early Lyme disease and human granulocytic ehrlichiosis in Wisconsin. J. Infect. Dis. 29: 1472– 1477.
3. Buller, R. S.,, M. Arens,, P. Himel,, C. D. Paddock,, J. W. Sumner,, Y. Rikihisa,, A. Unver,, M. Gaudreault-Keener,, F. A. Manian,, A. M. Liddell,, N. Schmulewitz,, and G. A. Storch. 1999. Ehrlichia ewingii, a newly recognized agent of human ehrlichiosis. N. Engl. J. Med. 341: 148– 155.
4. Carpenter, C. F.,, T. K. Gandhi,, L. Kuo Kong,, G. R. Corey,, S.-M. Chen,, D. H. Walker,, J. S. Dumler,, E. Breitschwerdt,, B. Hegarty,, and D. J. Sexton. 1999. The incidence of ehrlichial and rickettsial infections in patients with unexplained fever and recent history of tick bite in central North Carolina. J. Infect. Dis. 180: 900– 903.
5. des Vignes, F.,, J. Piesman,, R. Heffernan,, T. L. Schulze,, K. C. Stafford III,, and D. Fish. 2001. Effect of tick removal on transmission of Borrelia burgdorferi and Ehrlichia phagocytophila by Ixodes scapularis nymphs. J. Infect. Dis. 183: 773– 778.
6. McQuiston, J. H.,, C. D. Paddock,, R. C. Holman,, and J. E. Childs. 1999. The human ehrlichioses in the United States. Emerg. Infect. Dis. 5: 635– 642.
7. Parola, P.,, and D. Raoult. 2001. Ticks and tickborne bacterial diseases in humans: an emerging disease threat. Clin. Infect. Dis. 32: 897– 928.
8. Standaert, S. M.,, T. Yu,, M. A. Scott,, J. E. Childs,, C. D. Paddock,, W. L. Nicholson,, J. Singleton, Jr.,, and M. J. Blaser. 2000. Primary isolation of Ehrlichia chaffeensis from patients with febrile illnesses: clinical and molecular characteristics. J. Infect. Dis. 181: 1082– 1088.
1. Hjelle, B.,, and G. E. Glass. 2000. Outbreak of hantavirus infections in the Four Corners region of the United States in wake of the 1997-1998 El Niño-southern oscillation. J. Infect. Dis. 181: 1569– 1573.
2. Khan, A. S.,, R. F. Khabbaz,, L. R. Armstrong,, R. C. Holman,, S. P. Bauer,, J. Graber,, J. Strine,, G. Miller,, S. Reef,, J. Tappero,, R. E. Rollin,, S. T. Nichol,, S. R. Zaki,, R. T. Bryan,, L. E. Chapman,, C. J. Peters,, and T. G. Ksiazek. 1996. Hantavirus pulmonary syndrome: the first 100 cases. J. Infect. Dis. 173: 1297– 1303.
3. Mills, J. N.,, T. G. Ksiazek,, C. J. Peters,, and J. E. Childs. 1999. Long-term studies of hantavirus reservoir populations in the southwestern United States: a synthesis. Emerg. Infect. Dis. 5: 135– 142.
4. Mori, M.,, A. L. Rothman,, I. Kurane,, J. M. Montoya,, K. B. Nolte,, J. E. Morman,, D. C. Waite,, F. T. Koster,, and F. A. Ennis. 1999. High levels of cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary syndrome. J. Infect. Dis. 179: 295– 302.
5. Schmaljohn, C.,, and B. Hjelle. 1997. Hantaviruses: a global disease problem. Emerg. Infect. Dis. 3: 95– 104.
1. Anderson, R. M.,, C. A. Donnelly,, N. M. Ferguson,, M. E. J. Woolhouse,, C. J. Watt,, H. J. Uddy,, S. MaWhinny,, S. P. Dunstan,, T. R. E. Southwood,, J. W. Wilesmith,, J. B. M. Ryan,, L. J. Hoinville,, J. E. Hillerton,, A. R. Austin,, and G. A. H. Wells. 1996. Transmission dynamics and epidemiology of BSE in British cattle. Nature (London) 382: 779– 788.
2. Brown, P.,, M. Preece,, J. P. Brandel,, T. Sato,, L. McShane,, I. Zerr,, A. Fletcher,, R. G. Will,, M. Pocchiari,, N. R. Cashman,, J. H. d’Aignaux,, L. Cervenakova,, J. Fradkin,, L. B. Schonberger,, and S. J. Collins. 2000. Iatrogenic Creutzfeldt- Jakob disease at the millennium. Neurology 55: 1075– 1081.
3. Chapman, T.,, D. W. McKeel, Jr.,, and J. C. Morris. 2000. Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt-Jakob disease. Neurology 55: 1396– 1397.
4. Lloyd, S. E.,, O. N. Onwuazor,, J. A. Beck,, G. Mallinson,, M. Farrall,, P. Targonski,, J. Collinge,, and E. M. Fisher. 2001. Identification of multiple quantitative trait loci linked to prion disease incubation period in mice. Proc. Natl. Acad. Sci. USA 98: 6279– 6283.
5. Prusiner, S. B. 1995. The prion diseases. Sci. Am. 272: 48– 57.
6. Will, R. G.,, J. W. Ironside,, M. Zeidler,, S. N. Cousens,, K. Estibeiro,, A. Alperovitch,, S. Poser,, M. Pocchiari,, A. Hofman,, and P. G. Smith. 1996. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347: 921– 925.

Tables

Emerging and Reemerging Infectious Diseases
Citation: Gilligan P, Smiley M, Shapiro D. 2003. Emerging and Reemerging Infectious Diseases, p 354-406. In Cases in Medical Microbiology and Infectious Diseases, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816353.ch7
/content/10.1128/9781555816353.chap7.tab7
TABLE 7

EMERGING AND REEMERGING INFECTIOUS DISEASES

10.1128/9781555816353/tab7_thmb.gif
10.1128/9781555816353/tab7.gif
Generic image for table
TABLE 7

EMERGING AND REEMERGING INFECTIOUS DISEASES

Citation: Gilligan P, Smiley M, Shapiro D. 2003. Emerging and Reemerging Infectious Diseases, p 354-406. In Cases in Medical Microbiology and Infectious Diseases, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816353.ch7
/content/10.1128/9781555816353.chap7.tab-pg383
Untitled
10.1128/9781555816353/tab-pg383_thmb.gif
10.1128/9781555816353/tab-pg383.gif
Generic image for table
Untitled

Citation: Gilligan P, Smiley M, Shapiro D. 2003. Emerging and Reemerging Infectious Diseases, p 354-406. In Cases in Medical Microbiology and Infectious Diseases, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816353.ch7
/content/10.1128/9781555816353.chap7.tab-pg404
Untitled
10.1128/9781555816353/tab-pg404_thmb.gif
10.1128/9781555816353/tab-pg404.gif
Generic image for table
Untitled

Citation: Gilligan P, Smiley M, Shapiro D. 2003. Emerging and Reemerging Infectious Diseases, p 354-406. In Cases in Medical Microbiology and Infectious Diseases, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816353.ch7

Back to top
This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error